An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
Top Cited Papers
- 13 April 2015
- journal article
- letter
- Published by Springer Nature in Nature Medicine
- Vol. 21 (5), 492-497
- https://doi.org/10.1038/nm.3847
Abstract
Hemophilia A and B are inherited bleeding disorders characterized by deficiencies in procoagulant factor VIII (FVIII) or factor IX (FIX), respectively. There remains a substantial unmet medical need in hemophilia, especially in patients with inhibitory antibodies against replacement factor therapy, for novel and improved therapeutic agents that can be used prophylactically to provide effective hemostasis. Guided by reports suggesting that co-inheritance of prothrombotic mutations may ameliorate the clinical phenotype in hemophilia1,2,3,4,5,6,7,8,9, we developed an RNA interference (RNAi) therapeutic (ALN-AT3) targeting antithrombin (AT) as a means to promote hemostasis in hemophilia. When administered subcutaneously, ALN-AT3 showed potent, dose-dependent, and durable reduction of AT levels in wild-type mice, mice with hemophilia A, and nonhuman primates (NHPs). In NHPs, a 50% reduction in AT levels was achieved with weekly dosing at approximately 0.125 mg/kg, and a near-complete reduction in AT levels was achieved with weekly dosing at 1.5 mg/kg. Treatment with ALN-AT3 promoted hemostasis in mouse models of hemophilia and led to improved thrombin generation in an NHP model of hemophilia A with anti-factor VIII inhibitors. This investigational compound is currently in phase 1 clinical testing in subjects with hemophilia A or B.Keywords
This publication has 42 references indexed in Scilit:
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisNew England Journal of Medicine, 2013
- In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR)Silence, 2010
- Phosphatidylinositol Containing Lipidic Particles Reduces Immunogenicity and Catabolism of Factor VIII in Hemophilia A MiceThe AAPS Journal, 2010
- Interpatient Phenotypic Inconsistency in Severe Congenital Hemophilia: A Systematic Review of the Role of Inherited ThrombophiliaSeminars in Thrombosis and Hemostasis, 2009
- The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosisBlood, 2008
- Interfering with disease: a progress report on siRNA-based therapeuticsNature Reviews Drug Discovery, 2007
- Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and BThrombosis and Haemostasis, 2005
- The RNAi revolutionNature, 2004
- Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin, Protein C, Protein S Deficiency, or Activated Protein C ResistanceArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994